Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
NRG Oncology
Jonsson Comprehensive Cancer Center
M.D. Anderson Cancer Center
Jonsson Comprehensive Cancer Center
Abramson Cancer Center at Penn Medicine
M.D. Anderson Cancer Center
Second Affiliated Hospital, School of Medicine, Zhejiang University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Emory University
NRG Oncology
University of Utah
University of Wisconsin, Madison
M.D. Anderson Cancer Center
Mayo Clinic
Tianjin Medical University Cancer Institute and Hospital
Mayo Clinic
Washington University School of Medicine
Second Affiliated Hospital of Soochow University
M.D. Anderson Cancer Center
University of Utah
University of Chicago
Mayo Clinic
Uganda Cancer Institute
University of California, San Francisco
Mayo Clinic
M.D. Anderson Cancer Center
Mayo Clinic
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Zhejiang Cancer Hospital
Hebei Medical University Fourth Hospital
Corewell Health East
Ohio State University Comprehensive Cancer Center
Severance Hospital
Thomas Jefferson University
Maria Sklodowska-Curie National Research Institute of Oncology
Fudan University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of Utah
West Virginia University